LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-22 and is reviewed periodically as new material appears.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
== Capital crimes == In addition to the Penal Code, there are four Acts of Parliament that prescribe death as punishment for offences. According to the Think Centre, a Singaporean civil rights group, 70% of hangings are for drug-related offences. All eight hangings in 2017 were for drug-related offences that year, and 11 of 13 hangings in 2018 were also for drug-related offences.
Mohs surgery, developed in 1938 by general surgeon Frederic E. Mohs, is microscopically controlled surgery used to treat both common and rare types of skin cancer. During the surgery, after each removal of tissue and while the patient waits, the tissue is examined for cancer cells. That examination dictates the decision for additional tissue removal. Mohs surgery is the gold standard method for obtaining complete margin control during removal of a skin cancer (complete circumferential peripheral and deep margin assessment using frozen section histology). This method allows for the removal of skin cancer with a very narrow surgical margin and a high cure rate. The cure rate with Mohs surgery cited by most studies is between 97% and 99.8% for primary basal-cell carcinoma, the most common type of skin cancer. Mohs procedure is also used for squamous cell carcinoma, but with a lower cure rate. Recurrent basal-cell cancer has a lower cure rate with Mohs surgery, more in the range of 94%. It has been used in the removal of melanoma-in-situ (cure rate 77% to 98% depending on surgeon), and certain types of melanoma (cure rate 52%). Other indications for Mohs surgery include dermatofibrosarcoma protuberans, keratoacanthoma, spindle cell tumors, sebaceous carcinomas, microcystic adnexal carcinoma, merkel cell carcinoma, Paget's disease of the breast, atypical fibroxanthoma, and leiomyosarcoma. Because the Mohs procedure is micrographically controlled, it provides precise removal of the cancerous tissue, while healthy tissue is spared.
He told Gorbachev, "We understand the need for assurances to the countries in the East. If we maintain a presence in a Germany that is a part of NATO, there would be no extension of NATO's jurisdiction for forces of NATO one inch to the East." The following day, meeting Kohl in Moscow, Gorbachev voiced no fundamental objection to unification, provided Soviet concerns over borders, alliance structure, and the GDR's economic ties received due consideration; both German states, he observed, had absorbed the lessons of their shared history. Meanwhile, National Security Council staffer, Condoleezza Rice, plainly stated that the Soviets were in no position to resist German reunification. Reassurances from U.S. officials and Germany's financial aid payments sufficiently placated the Soviets at the time. The final settlement, worked out between Kohl and Gorbachev at Arkhyz in July 1990 and finalized that September, traded Soviet military withdrawal from East Germany for 12 billion deutschmarks plus an interest-free credit of another 3 billion—leading Deputy Secretary of Defense Robert Gates to remark that the Soviet Union had, quite literally, been "bribed out" of Europe. The concession provoked fury among Gorbachev's own advisers, such as Valentin Falin, who warned in a memorandum that NATO membership for a united Germany would "solidify the separation of European security" and give "impetus to NATO's advance to the Soviet Union's borders along the entire frontline."
Sources: en.wikipedia.org
telomeric silencing The repression of transcription of genes in regions adjacent to telomeres. Telomeres also appear to reduce the accessibility of subtelomeric chromatin to modification by DNA methyltransferases.
=== 2021: Olympic gold, second ATP Finals title === Zverev began his season in February with the ATP Cup, where he represented Germany with Jan-Lennard Struff, Kevin Krawietz and Andreas Mies to reach the semi-finals. In his first Grand Slam tournament appearance at the 2021 Australian Open, he defeated Marcos Giron, Maxime Cressy, Adrian Mannarino and Dušan Lajović. His run ended in the quarterfinals, where he lost to the eventual champion and world No. 1 Novak Djokovic. In March his first tournament was in Rotterdam, where he lost in the first round to Kazakh Alexander Bublik. He continued his performances in Acapulco, where he won his 14th ATP title by defeating Stefanos Tsitsipas in the final. At the tournament in Miami, he lost in the second round to Finland's Emil Ruusuvuori. At his first tournament in 2021 on clay in Monte Carlo, Zverev finished in the third round, losing to David Goffin. In Munich, he reached the quarterfinals, losing to the 107th ranked tennis player in the world, Ilya Ivashka. At the Madrid Open, Zverev defeated Rafael Nadal, Dominic Thiem, and Matteo Berrettini en route to his fourth Masters 1000 title and 15th career title. At the same tournament, he also reached his first semifinal in doubles at a Masters 1000, partnering with compatriot Tim Pütz, but withdrew from the match. He reached the quarterfinals of the Masters 1000 in Rome, losing to eventual tournament winner Rafael Nadal. In his second Grand Slam tournament of the year – in Paris, where he was seeded No.
The Hudson River Chains were a series of chain booms constructed across the Hudson River at West Point by Continental Army forces from 1776 to 1778 during the American Revolutionary War. These served as defenses preventing British naval vessels from sailing upriver and were overseen by the Highlands Department of the Continental Army. The first chain was destroyed by British forces in the aftermath of the Battle of Forts Clinton and Montgomery in October 1777. The more significant and successful was the Great Chain, constructed in 1778 and used through war's end in 1782. Two other barriers across the river, referred to as chevaux-de-frise, were undertaken by the Colonials; the first, between Fort Washington, on the island of Manhattan, and Fort Lee, in New Jersey, was completed in 1776 and shortly seized by the British; another was started in 1776 between Plum Point on the east bank and Pollepel Island north of West Point but abandoned in 1777 in favor of completion of the Great Chain nearby the following year.
Sources: en.wikipedia.org
== Function == This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. This enzyme participates in the Calvin cycle which is an autotrophic carbon fixation pathway.
== Procedure Steps == For anorectal fistulae, the surgeon begins by identifying the internal and external opening of the fistula. The external opening is usually on the patient's skin and can be identified in clinic. The internal opening is within the anus, and can be found while the surgeon examines the anorectal columns while the patient is under anesthesia. A methylene blue dye or a peroxide solution may be used to aid with this process. Once the openings of the tract are found, a thin metal probe is strung through. Using scissors or electrocautery, the surgeon then cores out the tunneling tract. At this point, the surgeon inspects the anal sphincters and closes any defects that were made during the procedure. The wound can then be left open to heal or closed by approximating the tissue back to its anatomic position with sutures.
Besides hemorrhagic stroke, myocardial infarction, coronary vasospasm, and sudden death have also rarely been reported with sympathomimetic ephedra compounds like pseudoephedrine and ephedrine. A 2005 meta-analysis found that pseudoephedrine at recommended doses had no meaningful effect on systolic or diastolic blood pressure in healthy individuals or people with controlled hypertension. Systolic blood pressure was found to slightly increase by 0.99 mm Hg on average and heart rate was found to slightly increase by 2.83 bpm on average. Conversely, there was no significant influence on diastolic blood pressure, which increased by 0.63 mg Hg. In people with controlled hypertension, systolic hypertension increased by a similar degree of 1.20 mm Hg. Immediate-release preparations, higher doses, being male, and shorter duration of use were all associated with greater cardiovascular effects. A small subset of individuals with autonomic instability, perhaps in turn resulting in greater adrenergic receptor sensitivity, may be substantially more sensitive to the cardiovascular effects of sympathomimetics. Subsequent to the 2005 meta-analysis, a 2015 systematic review and a 2018 meta-analysis found that pseudoephedrine at high doses (>170 mg) could increase heart rate and physical performance with larger effect sizes than lower doses. A 2007 Cochrane review assessed the side effects of short-term use of pseudoephedrine at recommended doses as a nasal decongestant.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.